Corcept submitted NDA for relacorilant to treat Cushing's syndrome, showing positive results in trials.

From Nasdaq: 2024-12-31 13:40:00

Corcept Therapeutics Incorporated submitted an NDA for relacorilant to treat Cushing’s syndrome. Positive results from trials showed improvements in symptoms with no serious adverse events. CORT stock has surged 56.6% this year. Potential approval for relacorilant could expand Corcept’s patient reach for Cushing’s syndrome and other cancers.

CORT’s revenue from Korlym increased by 42.1% in the first nine months of 2024, leading to a revised annual revenue guidance of $675-$700 million. Corcept’s Zacks Rank is currently a Strong Buy, with promising stocks like Bristol Myers Squibb and Rigel Pharmaceuticals also showing strong performance.

Take advantage of Zacks’ portfolio services with a $1 offer to access all picks and recommendations. Thousands have benefited from Zacks’ stock analysis services, which have shown significant gains in various sectors. Get insights into potential stock picks like Bristol Myers Squibb, Rigel Pharmaceuticals, and Corcept Therapeutics Incorporated.



Read more at Nasdaq: Corcept Submits Application for Another Cushing’s Syndrome Drug